LionBird

LionBird, headquartered in Tel Aviv, is an early-stage venture firm exclusively focused on digital health. The fund’s working assumption is that the most attractive opportunities in healthcare technology arise from structural inefficiencies in care delivery, payment, and clinical operations, and that software companies that solve those problems carefully and with real domain depth will compound durable advantages. For AI healthcare founders, that orientation gives LionBird a clear thesis-aligned identity.

The fund’s portfolio leans into provider-facing software, payer-facing tools, clinical operations platforms, and digital therapeutics where AI plays a substantive role. Companies that depend on real workflow integration, billing logic, or clinical evidence to generate value are favored. Pure consumer wellness, medical devices, and biotech are outside the mandate. Companies whose AI is decorative rather than central to the product will find diligence challenging.

Check sizes range from $1M to $5M at entry, deployed across pre-seed, seed, and Series A. LionBird leads and co-leads in priced rounds and reserves capital for follow-on. Geography spans Israel and the US, with portfolio companies typically operating with engineering teams in Israel and commercial centers in the US. Syndicate partners span Israeli and US digital health specialists, and the fund actively supports US commercial expansion through its network of provider, payer, and operator relationships.

The team includes investment partners with backgrounds in healthcare investing, operating roles inside digital health companies, and the US healthcare market more broadly. Board engagement tends to be active, with help focused on US go-to-market, payer and provider strategy, hiring, and downstream financing. The fund is comfortable supporting founders through the long sales cycles characteristic of enterprise healthcare buyers.

Founders should approach LionBird with a clear hypothesis about which structural inefficiency the product addresses, who the buyer is, and how AI is the substantive engine inside the product. Introductions through Israeli and US digital health VCs, portfolio CEOs, or healthcare operators are the highest-signal path in. The right time to engage is when the team is assembled, an early product is in motion, and the next round is being structured. Founders pitching consumer wellness, devices, or pure infrastructure plays without a healthcare angle will not find fit. Companies with no clear US commercial path, given the centrality of the US market to the fund’s thesis, will struggle. For founders building genuinely thoughtful digital health software with AI at the core, LionBird is among the most thesis-aligned and operationally engaged early-stage partners in the Israeli ecosystem.